Sector News

Tesaro and its new med Zejula are on the block

June 2, 2017
Life sciences

Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street Journal.

That’s Tesaro, whose PARP inhibitor Zejula won FDA approval in March. That med launched soon after at a price of $118,000 per year, which Tesaro touted as lower than its head-to-head rivals in ovarian cancer, AstraZeneca’s Lynparza and Clovis Oncology’s Rubraca.

Analysts have pegged Zejula, or niraparib, as one of 2017’s biggest launches, with 2022 sales of $1.9 billion. That’s an enticing prospect for bigger companies looking to beef up their oncology businesses, but that very fact could make it an expensive prospect, too. Thanks to a big stock runup since Tesaro rolled out top-line Zejula data last July, the company’s market value as of Thursday morning was $8 billion.

The WSJ’s sources say Tesaro has requested offers from a variety of potential bidders over the past few weeks—but they also say potential acquirers aren’t exactly falling over themselves to pursue a deal.

Price is potentially one reason, obviously. Another? Would-be buyers might be waiting for the American Society of Clinical Oncology meeting this weekend, where AstraZeneca will present data on Lynparza and Tesaro will post data on a Zejula combination with Merck’s blockbuster PD-1 therapy Keytruda.

Every other PARP hopeful in the running will roll out its own data, too, across a range of cancers that Zejula might eventually want to tap.

Still another reason for the supposedly lukewarm interest: Pfizer’s $14 billion deal for Medivation—and its PARP med talazoparib—has come in for criticism lately.

Zejula’s big sales projections rely on its ability to rack up new indications, including prostate cancer and breast cancer. And they rely on Zejula’s ability to stake out a piece of the PARP market. It’s a hot field, with more pipeline meds likely to add to the three competitors already jockeying for scripts; Pfizer’s forthcoming talazoparib, for instance.

AstraZeneca, meanwhile, is up for a new indication that would put it on more even footing with Zejula, which currently boasts a broader label. The U.K.-based drugmaker nabbed priority review at the FDA for use as a maintenance therapy, rather than third-line choice as it is now, and it could be positioning Zejula for an approval in patients without the BRCA mutation as well.

The fact that Pfizer has talazoparib on its way means it’s not the likeliest buyer for Tesaro, despite its willingness to consider deals of any and all sizes. Other possibilities? Gilead Sciences, which needs a big deal to rescue itself from hepatitis C decline, has said it’s interested in oncology, and Sanofi’s in the market for M&A up to $20 billion.

Then there’s Novartis, soon to have a cash stash after unloading Alcon, which doesn’t have a PARP drug in its pipeline. Or, just maybe Bristol-Myers Squibb, which has been bandied about as a takeover target itself, and doesn’t have a PARP drug, either.

Whether any of these deep-pocketed drugmakers would want to shell out for Tesaro remains to be seen, however. After ASCO, the picture could be clearer.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend